Skip to content
Search

Latest Stories

NAWP welcomes Boots’ move to cover staff HRT scripts cost

The National Association of Women Pharmacists (NAWP) has appreciated Boots’ move to make Hormone Replacement Treatment (HRT) prescriptions free of cost for its employees.

Boots is supporting team members experiencing menopausal symptoms by removing the barrier of prescription costs, an initiative that could help them save individuals up to £224 per year.


“Pharmacists should be aware that it is not just their patients who experience menopause, it is an issue in the workplace too. As around 50 per cent of the world’s population consists of women, even if some will not experience menopause themselves, there will be female colleagues who will do so at some point in their lives,” said NAWP.

The association has long been raising the profile of women’s health issues for working pharmacists and has published several factsheets to assist employed and locum pharmacists as well as their employers.

NAWP, therefore, welcomes the news that the largest employer of pharmacists in the UK, Boots, has announced that it will provide additional support for pharmacists and other team members who need Hormone Replacement Treatment (HRT).

Around 80 per cent of Boots’ 51,000 employees are women and around 8,600 Boots team members are currently in scope to access HRT which helps relieve the symptoms of menopause. From April 2022, Boots will cover the cost of its team members’ prescriptions for those able and wanting to take HRT.

In October 2021, the government announced that women in England would only have to pay one charge of £18.70 for up to a 12-month supply of hormone replacement therapy (HRT). But recently, pharmacy minister Maria Caulfield confirmed that the move would not be enacted until April 2023.

Prescriptions are free of charge in Wales, Scotland, and Northern Ireland, but most Boots team members are faced with a prescription charge from NHS England, so this will be an added benefit of working at Boots.

Daniela Rusalim, vice-president of NAWP and a pharmacist employed at Boots said: “This is a very welcome announcement of additional support from Boots for a health issue that impacts women at work. NAWP and the wider PDA are always pleased to give credit where it is due and welcome this initiative. We also welcome Boots stated aim to become a menopause-friendly employer.

"The pharmacist profession is two-thirds female and NAWP would like to see other employers in the UK introduce similar support for their employees.”

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less